Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep ...

The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company said. "Too ...

The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the ...

The FDA declared a shortage of popular weight-loss and diabetes drugs. Here's what that means for people who get generic ...

This precipitous sell-off has placed Lilly stock near its lowest levels in six months. Below, I'll explore what's been driving the sell-off, and assess whether Lilly has any catalysts that could make ...

The FDA has approved Eli Lillys Zepbound as the first weight-loss drug to treat obstructive sleep apnea, reshaping care for ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...